

# A role for casein kinase 1-epsilon in the motivational properties of opioids

Lisa R. Goldberg, Stacey L. Kirkpatrick, and Camron D. Bryant  
 Department of Pharmacology and Experimental Therapeutics, Boston University Medical School

## BACKGROUND

Casein kinase-1 (CK-1) is a family of serine/threonine-selective kinases that possess diverse molecular substrates and biological functions. Notably, CK-1 phosphorylates DARPP-32, a striatally abundant protein that integrates dopaminergic signaling in response to drugs of abuse. Recent studies demonstrate that the epsilon isoform of CK-1, Csnk1e, contributes to the locomotor stimulant properties of fentanyl, a selective mu opioid receptor agonist. We previously found that selective pharmacological inhibition of Csnk1e enhanced the locomotor stimulant properties of fentanyl, indicating a negative regulatory role for Csnk1e in drug-induced behavioral responses. Because shared neurobiological mechanisms mediate drug-induced locomotor activity and drug reward, locomotor activity can frequently be used as a proxy for identifying targets that are important for drug reward. Here, we tested the hypothesis that Csnk1e negatively regulates the motivational properties of fentanyl.

## MATERIALS AND METHODS

Csnk1e knockout, heterozygous, and wild-type mice were bred by heterozygote breeding. Twenty-four hours post-assessment of initial preference for the drug-paired side on Day 1, mice received fentanyl (0, 0.025, 0.05, 0.2 mg/kg, i.p.) on Days 2 and 4 on the drug-paired side, and saline (i.p.) on Days 3 and 5 on the other side (distinguished by floor textures). Seventy-two hours later (Day 8), mice were assessed for fentanyl CPP (Day 8-Day 1). Separate cohorts of mice were utilized for the hot plate assay. Mice were assessed for pain response (licking the hindpaw) on the hot plate (52.5°C) prior to drug exposure, and 10 minutes after fentanyl injection (0, 0.2, 0.4 mg/kg, i.p.).

## RESULTS

Csnk1e knockout mice showed an enhanced fentanyl reward compared to wild-type mice at a low dose (0.05 mg/kg, i.p.). The knockout mice also exhibited a significant reduction in fentanyl reward at the highest dose (0.2 mg/kg, i.p.), suggesting an enhanced sensitivity to the aversive properties of opiates that are observed following high doses. Additionally, no differences were observed in fentanyl analgesia in the 52.5°C hot plate assay (0-0.4 mg/kg, i.p.).

## SUMMARY

Csnk1e knockout mice showed a leftward shift in the inverted u-shaped curve for opioid reward, exhibiting enhanced reward at lower doses and significantly decreased reward at higher doses. No differences were observed in fentanyl analgesia, implicating a neural mechanism selective for dopaminergic reward circuitry. To gain further insight into the neural mechanism, we are testing the hypothesis that Csnk1e knockout mice show differential DARPP-32 signaling in response to fentanyl. Finally, we are using an unbiased transcriptome approach (mRNA sequencing) to generate novel hypotheses regarding the molecular mechanism that mediates Csnk1e-mediated inhibition of opioid reward.


## REFERENCES

- ❖ Bryant CD, Graham ME, Distler MG, Munoz MB, Li D, Vezina P, Sokoloff G, Palmer AA (2009). A role for casein kinase 1 epsilon in the locomotor stimulant response to methamphetamine. *Psychopharmacology* 203 (4): 703-11.
- ❖ Bryant CD, Parker CC, Zhou L, Olker C, Chandrasekaran RY, Wager TT, Bolivar VJ, Loudon AS, Vitaterna MH, Turek FW, Palmer AA (2012). *Csnk1e* is a genetic regulator of sensitivity to psychostimulants and opioids. *Neuropsychopharmacology* 37 (4): 1026-35.


FUNDING R00DA029635, T32GM008541

## 1. Enhanced sensitivity to opioid reward/aversion in Csnk1e knockout mice.


Day1	Day2	Day3	Day4	Day5	Day6	Day7	Day8
SAL	DRUG	SAL	DRUG	SAL	-	-	SAL
Initial pref.	Training				Consolid.		CPP




## 2. Altered dose-response relationship of opioid reward/aversion in Csnk1e knockout mice.



## 3. Dissection of conditioned opioid reward behavior in Csnk1e knockout mice.



## 4. Baseline pain sensitivity in Csnk1e knockout mice.



## 5. Opioid analgesia in Csnk1e knockout mice.

